Answers are grounded in this paper and cite their sources.
Local control of rhabdomyosarcoma in the perianal and perineal region (PRMS) is challenging due to the unfavorable tumor location, the often advanced stage of disease, the prevalence of alveolar histology with PAX3/FOXO1 fusion, and frequent regional lymph node (LN) involvement at presentation. Distant metastases are present at diagnosis in up to 49% of patients. Given the high risk of recurrence, the prognosis of patients with PRMS treated with multimodal treatment is poor, with a reported 5-year overall survival (OS) rate of 39%-52%. Due to the rarity of PRMS along with variations in treatment protocols over time and across different cooperative groups, we have developed consensus local treatment guidelines. This guideline is based on a comprehensive literature review and expert opinion and is endorsed by the International Soft-Tissue Sarcoma Consortium (INSTRuCT). It integrates insights from three leading pediatric oncology cooperative groups: the Cooperative Weichteilsarkom Studiengruppe (CWS; since December 2024 part of European pediatric Soft-tissue sarcoma Study Group [EpSSG]), Children's Oncology Group (COG), and EpSSG. This document addresses surgical therapy options, including biopsy, nodal staging, and various resection modalities, as well as options for radiotherapy, such as intensity-modulated radiation therapy, proton beam therapy, and brachytherapy.
No takes yet. Share an insight, caveat, or question.
Seitz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: